ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study.

MLA

Giladi, Nir, et al. “ND0612 (Levodopa/Carbidopa for Subcutaneous Infusion) in Patients with Parkinson’s Disease and Motor Response Fluctuations: A Randomized, Placebo-Controlled Phase 2 Study.” Parkinsonism & Related Disorders, vol. 91, Oct. 2021, pp. 139–45. EBSCOhost, https://doi.org/10.1016/j.parkreldis.2021.09.024.

APA

Giladi, N., Gurevich, T., Djaldetti, R., Adar, L., Case, R., Leibman-Barak, S., Sasson, N., & Caraco, Y. (2021). ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson’s disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism & Related Disorders, 91, 139–145. https://doi.org/10.1016/j.parkreldis.2021.09.024

Chicago

Giladi, Nir, Tanya Gurevich, Ruth Djaldetti, Liat Adar, Ryan Case, Shelly Leibman-Barak, Nissim Sasson, and Yoseph Caraco. 2021. “ND0612 (Levodopa/Carbidopa for Subcutaneous Infusion) in Patients with Parkinson’s Disease and Motor Response Fluctuations: A Randomized, Placebo-Controlled Phase 2 Study.” Parkinsonism & Related Disorders 91 (October): 139–45. doi:10.1016/j.parkreldis.2021.09.024.